While many systemic treatments are available for atopic dermatitis (AD), Dr Alexandra Golant focused her lecture on the latest advancements and evidence-based strategies for choosing the right therapy. She began with a series of cases and clinical images emphasizing the range of presentations that AD can take, which can create discrete endotypes within the AD population. Fortunately, scientific discoveries on the pathogenesis of AD and treatment targeting now mirror the range of clinical presentations, allowing for an individualized approach to selecting a systemic therapy. 

Dr Golant reviewed when to reach for systemic therapy guidelines but also emphasized the importance of documenting disease severity, quality-of-life impacts, and treatment targets. She presented data on key therapies, including dupilumab, which showed sustained efficacy over 2 years, and tralokinumab, which demonstrated effectiveness in patients with head and neck involvement. Emerging options like nemolizumab and lebrikizumab were discussed, showcasing their promising results in clinical trials for moderate-to-severe AD. Dr Golant concluded by stressing the importance of achieving optimal treatment targets within 3 to 6 months and tailoring therapy to each patient’s needs and disease characteristics to improve outcomes and quality of life.